Results 261 to 270 of about 226,969 (309)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2004
ZD-6474, one of a series of inhibitors of vascular endothelial growth factor receptor tyrosine kinase, which also has activity against the epidermal growth factor receptor tyrosine kinase, is under development by AstraZeneca for the potential treatment of solid tumors.
openaire +1 more source
ZD-6474, one of a series of inhibitors of vascular endothelial growth factor receptor tyrosine kinase, which also has activity against the epidermal growth factor receptor tyrosine kinase, is under development by AstraZeneca for the potential treatment of solid tumors.
openaire +1 more source
Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
Lancet, The, 2021Søren D Østergaard +2 more
exaly
Current opinion in investigational drugs (London, England : 2000), 2001
ZD-0473 (formerly JM-473 and AMD-473) is a sterically hindered platinum (II) complex designed and synthesized by Johnson Matthey Technology and the Cancer Research Campaign (CRC) and under development as a potential treatment for cisplatin-resistant cancer. AstraZeneca is developing both an i.v. and an oral formulation of ZD-0473.
openaire +1 more source
ZD-0473 (formerly JM-473 and AMD-473) is a sterically hindered platinum (II) complex designed and synthesized by Johnson Matthey Technology and the Cancer Research Campaign (CRC) and under development as a potential treatment for cisplatin-resistant cancer. AstraZeneca is developing both an i.v. and an oral formulation of ZD-0473.
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489].
openaire +1 more source
ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489].
openaire +1 more source
Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
Lancet, The, 2021Ivan Fan Ngai Hung, Gregory A Poland
exaly
Equity valuation: AstraZeneca, PLC
2023Esta dissertação tem como objetivo estimar o justo valor da ação da AstraZeneca, Plc (AZN) a 31 de dezembro de 2022. Após uma análise da empresa e do setor em que se insere, são apresentadas três abordagens para avaliar a empresa. A AstraZeneca, é uma multinacional inglesa que opera no setor farmacêutico e teve um grande envolvimento na crise pandémica
openaire +1 more source
IIC - International Review of Intellectual Property and Competition Law, 2014
openaire +1 more source
openaire +1 more source